1 Min Read
Nov 28 (Reuters) - Kyowa Hakko Kirin Co Ltd:
* KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB‘S BIOLOGICS LICENSE APPLICATION Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.